ArticlePrecision chemistry2026
Everolimus Delivery via Lignin Nanoparticles Enhances Antitumor Activity in Hormone Receptor-Positive Breast Cancer.
Article in Precision chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mTOR inhibitor everolimus improved progression-free survival in patients with hormone receptor-positive breast cancer resistant to hormone therapy. Despite initial success, everolimus has not yet realized its full therapeutic potential due to its associated toxicities and the development of resistance. Here, we exploited biocompatible lignin nanoparticles to enhance everolimus delivery and the mechanism of action in hormone receptor-positive breast cancer cells. Everolimus was released from the lignin nanoparticles in a concentration-dependent manner, following a Fickian diffusion-like model. The nanoparticles protected the drug from potential pH-induced degradation. Confocal microscopy confirmed the diffusion and cytoplasmic localization of lignin nanoparticles, as well as the efficient release of the drug. Everolimus release effectively inhibits the proliferation in breast cancer MCF7 cells. EVE/LNPs showed an improved in vitro antitumor effect compared to EVE against the MCF7 cell line (63 vs 81% survival rate at 10 nM). Under acidic pH conditions, the lignin nanoparticles underwent partial degradation, probably generating oligomers with potential modulating effects on mTOR and FOXM1. Molecular docking simulations showed that lignin oligomers could selectively interact with the ATP-binding cavity of mTOR. The affinity of these interactions was modulated by the redox state of the lignin oligomers, with the strongest bond being observed for quinone derivatives. This dual-action mechanism, which combines drug delivery and modulation of cellular signaling, offers a promising "on/off" switch approach to enhance everolimus-based cancer therapies. Further in vivo studies are warranted to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.